Aurinia Deferred Long Term Liab from 2010 to 2024
| AUPH Stock | USD 9.12 0.14 1.56% |
Deferred Long Term Liabilities | First Reported 1999-12-31 | Previous Quarter 560 K | Current Value 442 K | Quarterly Volatility 163.6 K |
Check Aurinia Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aurinia Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.2 M, Interest Expense of 2.9 M or Selling General Administrative of 204.8 M, as well as many indicators such as Price To Sales Ratio of 6.97, Dividend Yield of 0.0 or PTB Ratio of 3.58. Aurinia financial statements analysis is a perfect complement when working with Aurinia Pharmaceuticals Valuation or Volatility modules.
Aurinia | Deferred Long Term Liab |
Latest Aurinia Pharmaceuticals' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Aurinia Pharmaceuticals over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Aurinia Pharmaceuticals' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aurinia Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Aurinia Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 385,268 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 68.66 | |
| Mean Deviation | 205,476 | |
| Median | 442,000 | |
| Standard Deviation | 264,525 | |
| Sample Variance | 70B | |
| Range | 847K | |
| R-Value | 0.54 | |
| Mean Square Error | 53.3B | |
| R-Squared | 0.29 | |
| Significance | 0.04 | |
| Slope | 31,996 | |
| Total Sum of Squares | 979.6B |
Aurinia Deferred Long Term Liab History
About Aurinia Pharmaceuticals Financial Statements
Investors use fundamental indicators, such as Aurinia Pharmaceuticals' Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Aurinia Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 508.3 K | 533.7 K |
Currently Active Assets on Macroaxis
When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:Check out the analysis of Aurinia Pharmaceuticals Correlation against competitors. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.536 | Quarterly Revenue Growth 0.243 | Return On Assets (0.02) | Return On Equity (0.06) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.